Literature DB >> 9480838

Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma.

M P Lutz1, I B Esser, B B Flossmann-Kast, R Vogelmann, H Lührs, H Friess, M W Büchler, G Adler.   

Abstract

Src family tyrosine kinases participate in the regulation of cell adhesion, cell growth and differentiation. Here, we examine for the first time the potential role of Src for growth regulation of human pancreatic carcinoma cells. By immunohistochemical analysis, Src was overexpressed in 13/13 pancreatic carcinoma tissue but not in 6 normal pancreatic tissue specimen. In Western blots of total cellular extracts, Src protein expression was elevated in 14/17 carcinoma cell lines as compared to normal pancreas or cultured human pancreatic duct cells. Kinase activity was only detectable in cancer cells and did not correlate with the amount of kinase protein or with the expression of the regulatory kinase Csk, indicating that Src is not regulated through protein expression or through expression of Csk. The Src-specific tyrosine kinase inhibitor herbimycin A decreased cell growth in a dose-dependent manner. We suggest that Src family kinases participate in growth regulation of pancreatic cancer cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9480838     DOI: 10.1006/bbrc.1997.8043

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  71 in total

1.  Evidence for secretion-like coupling involving pp60src in the activation and maintenance of store-mediated Ca2+ entry in mouse pancreatic acinar cells.

Authors:  Pedro C Redondo; Ana I Lajas; Ginés M Salido; Antonio Gonzalez; Juan A Rosado; José A Pariente
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

Review 2.  Angiogenic signal during cardiac repair.

Authors:  Nilanjana Maulik
Journal:  Mol Cell Biochem       Date:  2004-09       Impact factor: 3.396

3.  Src kinase activation: A switched electrostatic network.

Authors:  Elif Ozkirimli; Carol Beth Post
Journal:  Protein Sci       Date:  2006-04-05       Impact factor: 6.725

4.  Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.

Authors:  Nagathihalli S Nagaraj; M Kay Washington; Nipun B Merchant
Journal:  Clin Cancer Res       Date:  2011-01-25       Impact factor: 12.531

5.  The importance of Src signaling in sarcoma.

Authors:  Quanchi Chen; Zifei Zhou; Liancheng Shan; Hui Zeng; Yingqi Hua; Zhengdong Cai
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

6.  Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma.

Authors:  Jason P Wong; Timothy J Stuhlmiller; Louise C Giffin; Carolina Lin; Rachele Bigi; Jichen Zhao; Weihe Zhang; Ariana G Bravo Cruz; Steven I Park; H Shelton Earp; Dirk P Dittmer; Stephen V Frye; Xiaodong Wang; Gary L Johnson; Blossom Damania
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-25       Impact factor: 11.205

7.  EGFR-mediated apoptosis via STAT3.

Authors:  Nicole M Jackson; Brian P Ceresa
Journal:  Exp Cell Res       Date:  2017-04-19       Impact factor: 3.905

8.  Ligand activation of alternatively spliced fibroblast growth factor receptor-1 modulates pancreatic adenocarcinoma cell malignancy.

Authors:  Selwyn M Vickers; Zhi-Qiang Huang; LeeAnn MacMillan-Crow; Jessica S Greendorfer; John A Thompson
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

9.  Srcasm inhibits Fyn-induced cutaneous carcinogenesis with modulation of Notch1 and p53.

Authors:  Liang Zhao; Weijie Li; Christine Marshall; Thomas Griffin; Matthew Hanson; Ryan Hick; Tzvete Dentchev; Erik Williams; Adrienne Werth; Christopher Miller; Hasan Bashir; Warren Pear; John T Seykora
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

Review 10.  Process of hepatic metastasis from pancreatic cancer: biology with clinical significance.

Authors:  Haojun Shi; Ji Li; Deliang Fu
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-07       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.